01:47 AM EDT, 10/29/2026 (MT Newswires) -- SenzaGen (SENZA.ST) agreed to acquire Alcyomics, a UK-based non-animal immunotoxicology testing provider for pharmaceutical development, for an initial purchase price of 28 million kronor. The deal will be funded through existing cash and a 25 million-krona directed issue of convertible bonds to SenzaGen's principal shareholder, Eiffel Investment Group, the Swedish biotechnology company said on Wednesday. The transaction is expected to close by Nov. 4.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.